Clinical bottom line
Anti-CD20 monoclonal antibodies represent a promising therapeutic option for adults with treatment-resistant minimal change disease (MCD), a condition traditionally managed with corticosteroids and immunosuppressants. Emerging evidence suggests that next-generation anti-CD20 agents may offer improved efficacy and safety profiles compared to older therapies, potentially enabling better disease control in refractory cases. However, current data remain preliminary and largely extrapolated from broader autoimmune disease contexts, warranting cautious interpretation and further validation in dedicated nephrology trials.
What the evidence shows
Minimal change disease in adults can be challenging to treat when patients exhibit resistance to standard corticosteroid therapy or relapse frequently. B cell depletion strategies targeting CD20 have gained attention due to their immunomodulatory effects. Rituximab, a chimeric anti-CD20 monoclonal antibody, has been used off-label with some success in refractory MCD, but limitations such as immunogenicity and infusion reactions have driven interest in next-generation humanized or fully human anti-CD20 antibodies (Du et al., 2017).
Next-generation anti-CD20 monoclonal antibodies, including agents with enhanced antibody-dependent cellular cytotoxicity and reduced immunogenicity, have demonstrated improved efficacy in autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (Senolt et al., 2019). For example, humanized anti-CD20 antibodies have been effective in severe, rituximab-resistant SLE cases (Tahir et al., 2005), suggesting potential applicability to other refractory immune-mediated kidney diseases like MCD.
Mechanistic studies highlight the role of transcription factors such as IRF8 in regulating the efficacy of anti-CD20 therapies by modulating B cell depletion and immune responses (2022 reviews on IRF8). These insights may inform patient stratification and optimization of treatment regimens in nephrology.
Although direct clinical trial data on next-generation anti-CD20 antibodies in adult MCD are limited, the accumulating evidence from autoimmune disease treatment supports their putative benefit in this setting. The ability to achieve deeper and more sustained B cell depletion with fewer adverse effects could translate into improved remission rates and reduced relapse frequency in treatment-resistant MCD.
Caveats and uncertainty
The evidence base for anti-CD20 monoclonal antibodies in adult MCD remains largely indirect and hypothesis-generating. Most clinical data derive from small case series, off-label use, or extrapolation from other autoimmune diseases rather than large randomized controlled trials specifically targeting MCD populations. The heterogeneity of MCD pathogenesis and patient immune profiles further complicates generalization.
Potential risks include infusion reactions, immunosuppression-related infections, and rare but serious adverse events such as progressive multifocal leukoencephalopathy. The long-term safety and optimal dosing schedules of next-generation anti-CD20 antibodies in nephrology are not well established.
Additionally, biomarkers predictive of response to anti-CD20 therapy in MCD are not yet validated, although IRF8 and related pathways offer promising avenues for future research.
How this may change practice
For nephrologists managing adults with treatment-resistant MCD, emerging anti-CD20 monoclonal antibodies may soon become an important adjunct or alternative to conventional immunosuppressants. Their use could be considered in select patients who have failed or are intolerant to steroids and other therapies, ideally within clinical trials or registries to build robust evidence.
Future integration of molecular and immunologic biomarkers may enable personalized treatment approaches, optimizing patient selection and monitoring. Awareness of next-generation anti-CD20 agents’ improved safety profiles may encourage earlier adoption once further clinical validation is available.
Ultimately, these therapies have the potential to reduce relapse rates, steroid exposure, and treatment-related toxicity, improving long-term kidney outcomes and quality of life in refractory MCD.